5 results about "Hypertensive Nephropathy" patented technology

The invention provides application of a Parp7 overexpression reagent in preparation of drugs for treating hypertensive nephropathy and protecting acute kidney injury caused by sepsis, and belongs to the technical field of biological medicine. According to the application disclosed by the invention, the pathological processes of the two diseases can be effectively relieved by increasing the expression level of Parp7 in the renal proximal tubule epithelial cells in a targeted manner. The invention further provides an adeno-associated virus vector comprising a renal proximal tubule epithelial cell specific promoter, a nucleotide sequence encoding Parp7 protein, and a transcription termination signal sequence. Experiments show that the strategy can significantly improve renal function indexes, relieve pathological injury of kidney tissues and inhibit local inflammatory response in an animal model. The invention provides a brand new target spot and gene therapy strategy for the treatment of hypertensive nephropathy and sepsis acute kidney injury.

The invention relates to the technical field of biological medicine, in particular to application of 4-VPS in preparation of a kit for screening and / or diagnosing hypertensive kidney injury. According to the invention, a detection sample of 4-VPS is peripheral blood, and the sample is convenient to collect, minimally invasive and easy to popularize clinically; meanwhile, functional experiments prove that 4-VPS can directly induce kidney injury, early diagnosis of hypertensive nephropathy is achieved through 4-VPS, a patient can receive intervention treatment in the early stage of the disease, the disease is delayed or even prevented from developing into the end-stage nephropathy, the requirement of the patient for subsequent dialysis treatment or kidney transplantation is reduced, personal medical expenditure is reduced, and the treatment cost is reduced. Meanwhile, consumption of social medical resources is reduced, and remarkable economic benefits are achieved.

The application discloses a new medical use of procyanidin B2 as a carbonic anhydrase IV (CA4) inhibitor. The application first confirms, by surface plasmon resonance (SPR) technology, that procyanidin B2 has direct and specific in-vitro combination with CA4 protein, and the equilibrium dissociation constant KD value is 7.51 μM. The application further confirms, by molecular docking, that the binding energy is-8.4 kcal / mol, which is superior to traditional inhibitors such as acetazolamide. The application further confirms, by molecular dynamics simulation, that the complex has high stability. The application further confirms, by HK-2 cell experiments, that procyanidin B2 can directly down-regulate the background expression of CA4 protein and re-regulate the abnormally high expression of CA4 induced by Ang II. Animal reference examples prove that the acacia extract containing procyanidin B2 can effectively improve the pathological damage of the kidney of SHR rats, reduce collagen deposition, reduce inflammatory factors and restore the folate level by inhibiting CA4. The application provides a new candidate drug molecule for treating renal fibrosis, hypertensive nephropathy and other related diseases by targeting CA4, and has a wide clinical application prospect.

The invention provides gRNA (guide Ribonucleic Acid) of a targeted AGT gene and application of the gRNA. The AGT gene comprises a human-derived AGT gene and a rat-derived AGT gene; wherein the sequence of the gRNA of the targeted human AGT gene is selected from any one of the following sequences: SEQ ID NOs: 64-105; the gRNA sequence of the AGT gene of the targeted rat source is selected from any one of the following sequences: SEQ ID NOs: 1-63. The gRNA can reduce the expression of the human / rat AGT gene through a CRISPR-Cas (clustered regularly interspaced short palindromic repeats-associated proteins) gene editing system. The gRNA is used for preparing medicines for treating hypertension or diseases (such as hypertensive heart disease, coronary heart disease, cerebral apoplexy, hypertensive nephropathy and hypertensive retinopathy) caused by hypertension, and has the advantages of lasting and stable curative effect, small adverse reaction, low treatment frequency, good patient compliance and low long-term treatment cost.

The invention relates to the technical field of biological medicine, in particular to application of AVE0991 in preparation of a new target medicine for preventing and / or treating hypertension kidney injury. The invention discovers and verifies that AVE0991 can specifically inhibit the formation of neutrophil extracellular traps (NETs) for the first time, especially under pathological conditions of renin-angiotensin system (RAS) imbalance or angiotensin II (Ang II) overexpression. The NETs inhibitory activity of AVE0991 is combined with the specific disease field of hypertension and renal injury caused by hypertension, and the brand new application potential of AVE0991 in prevention or treatment of hypertension-related renal injury (such as Ang II dependent hypertensive nephropathy) is defined.